S ubclinical hypothyroidism (SCH) and hypert t thyroidism represent the earliest stages of thyt t roid dysfunction.
S ubclinical hypothyroidism (SCH) and hypert t thyroidism represent the earliest stages of thyt t roid dysfunction.
1 SCH is defined by the finding of elevated serum thyrotropin (TSH) concentrations associated with normal free thyroid hormone levels and a lack of clinical signs and symptoms of hypothyroidt t ism.
2t4 SCH is usually detected during the followtup of patients with a history of thyroid disease or as a result of biochemical screening for nonspecific symptoms. 5 Whether SCH has any demonstrable effect on serum lipid concentrations has been controversial.
2,3,5t10 Several reports have shown that patients with SCH have a disturbed lipid metabolism, including elevated serum levels of total cholesterol (TC) 7,11t15 and lowtdensity lit t poproteintcholesterol (LDLtC). 7,12t16 Such changes are
Plasma homocysteine concentrations and serum lipid profile as atherosclerotic risk factors in subclinical hypothyroidism

BACKGROUND AND OBJECTIVES:
Because subclinical thyroid dysfunction may be a risk factor for cardiovas--cular disease, we evaluated the atherosclerosis tendency in subclinical hypothyroid (SCH) patients.
PATIENTS AND METHODS:
Fifty-three subclinical hypothyroid patients (serum thyrotropin [TSH] concentra--tions >4.12 mU/L) were compared with a control group of 50 euthyroid subjects whose age, sex and body mass indices were similar to the patient group. We tested whether serum TSH concentrations were correlated with plasma total homocysteine concentration (tHcy), low-density lipoprotein cholesterol (LDL-C), very low-density lipoprotein cholesterol (VLDL-C), high-density lipoprotein cholesterol (HDL-C), total cholesterol (TC) and tri--glycerides (TG).
RESULTS:
There was a significant statistical difference between the patient and control groups for normal free T4 (1. generally recognised as risk factors for atherosclerosis and coronary heart disease.
16
Homocysteine (Hcy) is formed during the metabot t lism of methionine, a sulfurtcontaining essential amino acid. 17 Many investigators have reported a significant association between hyperhomocysteinemia and cart t diovascular disease.
18t23 Elevated plasma total homocyst t teine (tHcy) levels have been reported in overt hypothyt t roidism, 24 and have been proposed as an independent risk factors for cardiovascular disease. 25 Whether SCH is a risk factor for premature cardiovascular disease is controversial. 2 We conducted this study to see whether there is a tendency toward atherosclerosis in SCH. The serum lipid profile and plasma tHcy concentrations of SCH patients and a euthyroid control group were compared. We also investigated whether there was a correlation between serum TSH and serum lipid profile or serum TSH and plasma tHcy values in SCH patients.
METHODS
We studied 53 SCH patients (47 women and 6 men), aged 40.8±12.1 years and with a mean BMI of 26.2±4.6 kg/m 2 (Table 1) . SCH was established by TSH levels >4.12 mU/mL 26 and normal free T3 (FT3) and T4 (FT4) levels in two consecutive measurements. There was no history of thyroidectomy (total or subtotal) or prior exposure to radioiodine or external radiation in any of the patients included in the study. Thirteen of the female patients were posttmenopausal but none was receiving hormone replacement therapy. None of the participants was diagnosed with neoplastic, renal, liver disease, diabetes mellitus or familial hypercholesterolt t emia. Subjects receiving any drugs or who smoked were excluded from the study. Fifty aget and sextmatched healthy individuals were used as controls in baseline measurements. The control group consisted of 43 women (9 postmenopausal) and 7 men. The mean age of the controls was 38.2±10.6 years and the mean BMI was 25.1±5.4 kg/m 2 . Informed consent was obtained from all subjects. A local ethics committee approved the study.
Serum samples were collected in the fasting state, immediately put on ice and processed within 30 mint t utes. Thereafter, they were kept frozen at t20ºC. Plasma tHcy concentration was measured by hightperformance liquid chromatography (Agilent 1100 series, Germany). The reference interval was 5t14 µmol/L. The intratast t say and intertassay coefficients of variation for tHcy were 2% and 4.2%, respectively. An upper reference limit from a published study for TSH of 4.12 mU/L, 26 which was accepted for a multicultural population, was used in selecting individuals for the SCH group. Serum TSH, FT3, FT4 concentrations were measured by a chemiluminescent microparticle immunassay on an Architect i2000 analyzer (Abbott, Texas, USA). Reference intervals provided by the manufacturer were TSH 0.35t4.94 mU/L, FT3 1.71t3.71 pg/mL, and serum FT4 0.70t1.48 ng/dL. The sensitivities of the TSH, FT3, FT4 were 0.0025 mU/L, 1 pg/mL, and 0.4 ng/dL, respectively. The intratassay coefficients of variation for TSH, FT3, and FT4 were 1.7%, 2.7%, and 3.2%, respectively.
Serum TC (reference range, 112t200 mg/dL) and triglyceride (TG) (reference range, 50t179 mg/dL) were determined by enzymatic colorimetric assay on an Aeroset analyzer (Abbott, Texas, USA). Hightdensity lipoprotein cholesterol (HDLtC) (reference range, 28t 75 mg/dL) was determined enzymatically in the supert t natant after precipitation of other lipoproteins. Very lowtdensity lipoprotein cholesterol (VLDLtC) was calt t culated using the TG/5 formula and LDLtC was calt t culated using the Friedewald formula. 27 The intratassay coefficients of variation for TC, TG, and HDLtC were 0.7% for high concentration, 1.0% for low concentrat t tion, 0.5% for high concentration, 0.8% for low concent t tration, 1.58% for high concentration, 1.7% for normal concentration, and 1.85% for low concentration, respect t tively. Serum creatinine (reference interval, 0.6t1.3 mg/ dL) concentration was measured by the Jaffe method on an Aeroset analyzer (Abbott, Texas, USA). Serum vitat t min B12 and folic acid were determined by Access fullt automatic chemiluminescent assay (Beckman Coulture, Chaska, USA). Reference intervals were 160t980 pg/ mL for vitamin B12 and 0t3 ng/mL for folic acid.
The data for the SCH and control groups were comt t pared by Student' s t test and the Wilcoxon signedtrank test. Student' s t test was used for comparison of group means with a normal distribution, while a Wilcoxon signedtrank test was used for comparison of means with nontnormal distributions. The Spearman rank correlat t tion on the entire data set as well as within groups was used to test whether TSH was correlated with TC, LDLtC, HDLtC, TG, VLDLtC, TC/HDLtC, LDLt C/HDLtC, and tHcy. P values less than .05 were cont t sidered statistically significant.
RESULTS
SCH patients had significantly lower FT4 (although within the normal range) and higher TSH levels than the control group (Table 1) . The mean plasma tHcy levels in patients were not significantly different than in controls (Table 2) . Mean serum levels of TC, TG, LDLtC, and the ratio of TC/HDLtC in patients were significantly different from the values in controls. Serum mean levels of VLDLtC, HDLtC, and the rat t tio of LDLtC/HDLtC were not significantly different from the values in controls. Across all participants TSH was positively correlated with TC, LDLtC, TC/HDLt C, LDLtC/HDLtC, and plasma tHcy concentrations (Table 3) . Correlations were not found between serum TSH concentration and serum TG and VLDLtC valt t ues.
DISCUSSION
Hypothyroidism is a progressive disorder presenting with different degrees of thyroid failure and metabolic consequences. 28 SCH is defined as an elevation in set t rum TSH above the upper limit of reference range with 30 and hypertension. 29 In addition, several casetcontrol, crosstsectional and prospective studies have consist t tently indicated that hyperhomocysteinemia is an int t dependent risk factor for the progression of vascular disease. 29 Overt hypothyroidism has been found to be assot t ciated with cardiovascular disease.
11 Whether SCH is related to the risk for cardiovascular disease is cont t troversial. It is well known that thyroid hormone has pervasive effects on the transport of the plasma lipot t proteins. 31 Cholesterol and LDL typically accumulate in the plasma of patients with hypothyroidism because thyroid hormone stimulates LDL receptor activity.
10,31
Thyroid hormone also influences the transport of TGt rich lipoproteins through its effects on the lipoprotein lipase enzyme system. Hepatic lipase has also been shown to decrease in severe thyroid deficiency and to increase after Ltthyroxine administration. 31 Hak et al 11
showed that SCH was present in 10.8% of participants and was associated with a greater agetadjusted prevat t lence of aortic atherosclerosis (odds ratio, 1.7 [95% CI, 1.1 to 2.6]) and myocardial infarction (odds ratio, 2.3 [CI, 1.3 to 4.0]). Miura et al 32 diagnosed 97 patients with CHD by coronary angiography (CHD group) and compared them with 103 healthy subjects matched for age, sex and body mass index (control group). They observed a significant decrease in serum FT3 and FT4 levels in patients with CHD that was associated with increased serum TSH.
Some studies 10, 12, 16 suggest that high TSH is associt t ated with deleterious changes in serum lipids, which are considered to be an important cardiovascular risk factor, particularly HDLtC, LDLtC, and the ratio of LDLtC to HDLtC. However, few studies 33, 34 have suggested that the majority of patients with SCH did not differ from controls in risk factors for coronary heart disease (e.g. TC, LDLtC, TK/HDLtC, LDLtC/HDLtC). Previous studies of thyroid dysfunction and TG levels have also been conflicting. Compared with individuals with normal thyroid function, TG levels have been ret t ported to be high 6,15 or unchanged 3,7,10,13,14 among those with biochemical evidence of SCH. In many previous clinical studies, 3 ,6,7,12,13,15,34 HDLtC has been reported to be unchanged among SCH patients.
We demonstrated that mean serum levels of TC, TG, LDLtC, and the ratio of TC/HDLtC in patients with SCH were significantly different from the values Table 4 . Summary of studies comparing plasma total homocysteine levels in patients with subclinical hypothyroidism and control subjects.
Number of patients and controls
Total homocysteine (µmol/L) 22 Numerous retrospective and prot t spective studies have consistently found a relationship between mild hyperhomocysteinemia (fasting or after oral methionine loading) and cardiovascular disease or alltcause mortality. Starting at a plasma tHcy cont t centration of approximately 10 µmol/L, an associated risk increase follows a linear dosetresponse relationship with no specific threshold level.
22 Although 30 years have elapsed since hyperhomocysteinemia (and hot t mocysteinuria) were first associated with an increased risk of atherothrombotic vascular disease, it is only ret t cently that sufficient evidence has mounted to suggest that the association is independent and dosetrelated, and it remains to be established whether it is causal and modifiable.
18 If a causal relationship does prove to exist between tHcy and cardiovascular disease, the biologit t cal mechanism(s) remains to be established. 35 Several mechanism have been proposed to contribute to the vascular toxicity of homocysteine, including platelet agt t gregation, increased coagulation or reduced thrombolyt t sis, endothelial dysfunction, and effects on the blood vessel wall. 36 Evidence now indicates that hyperhomot t cysteinemia, which occurs in approximately 5% to 7% of the general population, is an important, independent risk factor for atherosclerosis and thrombotic disease. 37 Lindeman et al 38 point out that thyroid status may be an important determinant of serum/plasma tHcy cont t centrations. The tHcy concentration appears to be int t creased in hypothyroidism and decreased in hyperthyt t roidism. Deicher and Vierhaper 39 reported that patients with SCH did not demonstrate improvement in fasting homocysteine levels after treatment with levothyroxt t ine. Meek and Smallridge 40 reported that levothyroxine treatment with subclinical hypothyroidism did not alter homocysteine levels in the fasting or posttmethionine states.
Several studies 29, 34, 38, 41 have been published where subjects with SCH were compared against normal eut t thyroid subjects to determine if there was a continuum of change in serum tHcy concentrations in those with SCH as opposed to an increase that occurs only when overt hypothyroidism exists. Although there were cort t relations between serum TSH and tHcy in all part t ticipants in these studies, there were no significant dift t ferences between cases and controls. Aldasouqi et al 42 found no association between subclinical hypothyroidt t ism and hyperhomocysteinemia. The findings of previt t ous studies, as well as our current study, are summat t rized in Table 4 . The results of our study confirm the findings of the previous studies.
Published retrospective studies demonstrate a stronger association between tHcy and CHD than prospective studies.
18,35,43 A major concern is that tHcy levels may rise after tissue damage; thus, retrospective studies of CHD patients may show elevated tHcy valt t ues as a result of, not a cause of, the coronary events. 43 One published report indicated that patients with SCH had homocysteine levels that were higher than those in normal control subjects and improved signifit t 44 The purpose of our prospective study was to examt t ine the effect of SCH on serum tHcy concentrations after adjusting for differences in gender, age and ethnict t ity. Additionally, serum folate, vitamin B12, and creatit t nine concentrations were also adjusted. A comparison had been made of selected CHD risk factors in male and female participants with SCH versus those with control group. In the present study, serum TSH levels were positively correlated with tHcy levels. Our study population consisted of adult patients (mean age of 40 years for the SCH group, of 38 years for the control group) who had previously not taken any drug and did not smoke. Serum TSH levels were greater than 4.12 mU/L and both FT3 and FT4 levels were normal in all participitants. Thus, our population was selected more rigoriously than the population in some other studies. There is no consensus on the relationship between SCH and CHD, although many studies have been performed. Only longtterm biochemical monitoring will prove the relationship. However, our study contributes informat t tion towards establishing an association between SCH and CHD. We have demonstrated higher serum levels of TC, TG, LDLtC in SCH patients. Research from experimental animals, laboratory investigations, epit t demiology, and genetic forms of hypercholesterolemia indicate that elevated LDL cholesterol is a major cause of CHD. In addition, recent clinical trials robustly show that LDLtlowering therapy reduces the risk for CHD. 45 For these reasons, focusing on LDL values in SCH pat t tients is important.
In conclusion, in the present study, homocysteine levels were not elevated in the majority of patients with SCH. We found no differences in plasma tHcy concent t trations between the SCH group compared with the control group. Our results suggest that the atherogenict t ity of SCH is not mediated by hyperhomocysteinemia. Associated hyperlipidemia may explain the observed increased risk of coronary artery disease in patients with SCH.
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